logo BDSP

Base documentaire

  1. Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections.

    Article, Communication - En anglais

    Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA, 1998/09/24.

    Study Objective

    To evaluate the efficacy and cost of treatment with two bêta-lactam/bêta-lactamase-inhibitor combinations.


    Retrospective, open-label multicenter study.


    Fifty-four hospitals across the United States.


    Eight hundred ninety patients with skin and soft tissue, intraabdominal, gynecologic, respiratory, urinary tract, or other infections that required parenteral antibiotic therapy.


    Patients were administered either ampicillin-sulbactam 1.5 or 3.0 g every 6 hours or ticarcillin-clavulanate 3.1 g every 6 hours.

    Measurements and Main Results

    The agents did not differ significantly in efficacy for most infections ; although, ampicillin-sulbactam was bacteriologically superior to ticarcillin-clavulanate in the treatment of intraabdominal infections (p=0.0011).

    Costs of ampicillin-sulbactam, particularly the 1.5-g dose, were lower than those of ticarcillin-clavulanate for skin and soft tissue (p<0.001), intraabdominal (p=0.005), and respiratory tract (p<0.001) infections.


    Ampicillin-sulbactam provides effective coverage for patients with the above infections and is as effective as the broader-spectrum agent.

    Mots-clés Pascal : Ampicilline, Interaction médicamenteuse, Sulbactam, Ticarcilline, Acide clavulanique, Inhibiteur enzyme, bêta-Lactamase, Hydrolases, Enzyme, Antibiotique, Homme, Chimiothérapie, Hospitalisation, Analyse coût efficacité, Analyse économique, Economie santé, Etude multicentrique, Efficacité traitement, Pénicilline dérivé, bêta-Lactamines, Association médicamenteuse, Antibactérien, Infection, Etats Unis, Amérique du Nord, Amérique

    Mots-clés Pascal anglais : Ampicillin, Drug interaction, Sulbactam, Ticarcillin, Clavulanic acid, Enzyme inhibitor, bêta-Lactamase, Hydrolases, Enzyme, Antibiotic, Human, Chemotherapy, Hospitalization, Cost efficiency analysis, Economic analysis, Health economy, Multicenter study, Treatment efficiency, Penicillin derivatives, bêta-Lactams, Drug combination, Antibacterial agent, Infection, United States, North America, America

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0321452

    Code Inist : 002B02S02. Création : 16/11/1999.